For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$47.67
Thesis
Scholar Rock develops myostatin-targeting biologics aimed at preserving muscle, with relevance to metabolic and neuromuscular disease. Its lead asset positions the company at the intersection of muscle biology and the obesity treatment landscape.
Catalysts
- Apitegromab regulatory and label progress
- Muscle-preservation data in combination with weight-loss therapies
- Pipeline expansion across neuromuscular and metabolic indications
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- May 7Financial resultsSEC
8-K filing (items 2.02/7.01/9.01) reporting financial results.